Stifel initiates NewAmsterdam stock with Buy rating, $44 target

Stifel initiated coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and a $44 price target, citing the potential of its lead drug candidate, obicetrapib, in the lipid-lowering market and anticipating positive outcomes from the PREVAIL trial. The firm highlights the company's strong funding and management, suggesting a low risk of downside surprise. This positive outlook aligns with recent developments, including positive sub-study results showing significant reductions in Alzheimer's biomarkers and favorable outcomes from Phase 3 trials demonstrating LDL-C lowering effects.

Analysis

Stifel has initiated coverage on NewAmsterdam Pharma (NAMS) with a Buy rating and a $44.00 price target, significantly above its current trading price of $20.16 and within a strong analyst consensus range of $37.11 to $52.68, reflecting considerable upside potential. This positive outlook is underpinned by NAMS's status as a late-stage pharmaceutical company focused on cardiovascular treatments, with its lead drug candidate, obicetrapib, showing substantial promise in the expanding lipid-lowering market; InvestingPro data further supports this positive sentiment, noting five analysts have recently revised earnings expectations upward for NAMS. Regulatory filings for obicetrapib are anticipated in the second half of 2025 or the first half of 2026, with pivotal PREVAIL trial outcomes expected by late 2026 or early 2027, which Stifel believes could significantly differentiate the drug. Despite historical industry setbacks with similar mechanisms of action, Stifel views obicetrapib and its PREVAIL study design as fundamentally different, assigning a high probability of demonstrating substantial relative risk reduction and citing a very low risk of downside surprise due to the drug's established safety profile and experienced management. The analysts suggest current market conditions, following a share price pull-in post-BROADWAY trial updates, present an attractive entry point for investors. NAMS's financial position is robust, characterized by an InvestingPro current ratio of 19.98, minimal debt exposure, and a $2.27 billion market capitalization, which mitigates financial risks associated with ongoing development and, according to Stifel, potentially positions the company for future mergers and acquisitions activity. Recent positive clinical developments include obicetrapib demonstrating significant reductions in the Alzheimer’s disease biomarker p-tau217 in a Phase 3 BROADWAY sub-study, particularly in ApoE4 carriers, and achieving significant LDL-C lowering in the broader BROADWAY and TANDEM Phase 3 trials. This bullish stance is echoed by other firms, with Cantor Fitzgerald initiating with an Overweight rating and a $42 target, and RBC Capital reiterating an Outperform rating with a $38 target. The strategic board appointment of Adele Gulfo further strengthens the company's commercialization expertise. While InvestingPro's Fair Value analysis suggests NAMS currently trades near its fair value, the stock's low beta of -0.02 indicates limited correlation with broader market movements, offering a distinct risk profile.

Key Decisions for Investors

• Investors should consider the compelling case for NewAmsterdam Pharma, highlighted by Stifel's $44 price target which suggests significant upside from its $20.16 trading level, reinforced by upward earnings revisions and a chorus of positive analyst ratings.
• Key milestones to monitor closely include the anticipated regulatory filings for obicetrapib in H2 2025/H1 2026 and the crucial PREVAIL trial read-out by late 2026/early 2027, which are pivotal for value realization and market differentiation.
• The company's strong financial footing, with a current ratio of 19.98 and minimal debt, alongside the emerging data on obicetrapib's potential utility in Alzheimer's disease, offer additional layers of support and upside potential to the core cardiovascular thesis.